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Chimeric antigen receptors (CARs) operably link T cell
activation domains to the antigen recognition properties
of an antibody, thereby redirecting T lymphocytes to
cells expressing the antigen. B cell maturation antigen
(BCMA) is an attractive CAR T cell target to treat
patients with multiple myeloma. Nearly all multiple
myeloma tumor cells express BCMA, while normal tis-
sue expression is restricted to plasma cells and a subset
of mature B cells. We tested four candidate anti-BCMA
CARs each comprised of unique single chain variable
fragments from antibodies specific to BCMA fused to
CD3zeta and CD137 (4-1BB) signaling domains. Candi-
date anti-BCMA CARs were introduced into T cells via
lentiviral vector technology, and the transduced T cells
expanded using a scalable clinical manufacturing pro-
cess. At the end of culture all four candidates demon-
strated equivalent transduction efficiencies and released
cytokines specifically in response to BCMA-positive
multiple myeloma cell lines. One candidate, bb2121, was
selected for further studies based on the robust fre-
quency of CAR-positive cells (57.0% +/- 4.5%), and
superior in vitro cytolytic activity against the multiple
myeloma cell line RPMI-8226 after co-incubation at a
10:1 effector to target ratio (77.4%, P < 0.0001). To eval-
uate the anti-tumor activity of bb2121 in vivo, we
employed a murine xenograft model in which 107
RPMI-8226 cells were subcutaneously implanted in NSG
mice eighteen days prior to CAR T cell treatment,
resulting in tumor volumes of 95 mm3 at the time of
infusion. In this setting, a single intravenous treatment
of 5.2 × 106 bb2121 anti-BCMA CAR+ T cells resulted
in rapid tumor infiltration, followed by involution and
complete tumor clearance after nineteen days. All mice
treated with bb2121 anti-BCMA CAR T cells remained
tumor free for the study duration (85 days). In contrast,
bortezomib (a current standard of care for multiple
myeloma) merely suppressed tumor growth during
administration and tumors progressed in all mice by day
fifty (n = 10). These data demonstrate the effectiveness
of our lentivirus-based CAR T cell manufacturing pro-
cess and support the further development of bb2121 for
the treatment of patients with multiple myeloma.
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